EXJADE Delivers Significant Efficacy in Treating Iron Toxicity for Patients With Aplastic Anemia

EXJADE reduces serum ferritin levels

In 2010, the 1-year EPIC study showed that EXJADE effectively reduced serum ferritin levels in patients with aplastic anemia (n=116).1

APLASTIC
ANEMIA 1

-964
µg/L at 1 year
P<0.001 (n=116)
based on LOCF
analysis

Serum Ferritin Reduced Over 1 Year by EXJADE

Serum Ferritin Reductions in Aplastic Anemia1
Serum ferritin reduction with EXJADE
Patients experienced dose-dependent reduction1
Significant reduction (P<0.0001) in serum ferritin levels2

In this prospective, multicenter, open-label, 1-year study, 1744 iron-overloaded patients with various-dependent anemias, including 116 patients with aplastic anemia, were enrolled to assess the change in serum ferritin levels from baseline to 52 weeks.1

EXJADE has shown efficacy in reducing liver iron concentration levels

In 2007, a 1-year study in patients across a range of anemias (N=184) showed that EXJADE reduced liver iron concentration in with rare anemia patients, including aplastic anemia.3

EXJADE Reduces Liver Iron Concentration in Patients
With Rare Anemias (including aplastic anemia)2
EXJADE Efficacy in Reducing Liver Iron Concentration Levels

In a 1-year open-label, noncomparative study, 184 transfusion-dependent patientswith b thalassemia (n=85), MDS (n=47), Diamond-Blackfan (n=30), and other inherited or acquired chronic anemias (n=22) were enrolled to assess the change in LIC from baseline to the end of the study.2

TAILORED CHELATION
THERAPY

Meet your patients’
needs with EXJADE.

Learn more

DIFFERENCES BETWEEN
APLASTIC AND
OTHER ANEMIAS

A variety of rare
anemias exist, each
with their own specific
characteristics.

Learn more

SAFETY PROFILE
ACROSS ANEMIAS

Learn more